Pharmacogenetic Practice of Anticancer Drugs: Multiple Approaches for an Accurate and Comprehensive Genotyping

References

• Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM. Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther. 2021;109(3):591–604. doi:10.1002/cpt.2069
   PubMed Web of Science ®Google Scholar
• Dean L. Irinotecan therapy and UGT1A1 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Varughese LA, Lau-Min KS, Cambareri C, et al. DPYD and UGT1A1 pharmacogenetic testing in patients with gastrointestinal malignancies: an overview of the evidence and considerations for clinical implementation. Pharmacotherapy. 2020;40(11):1108–1129. doi:10.1002/phar.2463
   PubMed Web of Science ®Google Scholar
• Mhandire DZ, Goey AKL. The value of pharmacogenetics to reduce drug-related toxicity in cancer patients. Mol Diagn Ther. 2022;26(2):137–151. doi:10.1007/s40291-021-00575-x
   PubMed Web of Science ®Google Scholar
• Begré UBM, Jörger M, Aebi S, Amstutz U, Largiadèr CR. Clinical implementation of DPYD pharmacogenetic testing to prevent early-onset fluoropyrimidine-related toxicity in cancer patients in Switzerland. Front Pharmacol. 2022;13:885259. doi:10.3389/fphar.2022.885259
   PubMed Web of Science ®Google Scholar
• Wigle TJ, Povitz BL, Medwid S, et al. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clin Transl Sci. 2021;14(4):1338–1348. doi:10.1111/cts.12981
   PubMed Web of Science ®Google Scholar
• Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz HJ, Milano G. All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide. JCO Oncol Pract. 2020;16(12):793–798. doi:10.1200/OP.20.00553
   PubMedGoogle Scholar
• Carrato A. Precision medicine: UGT1A1 genotyping to better manage irinotecan-induced toxicity. JCO Oncol Pract. 2022;18(4):278–280. doi:10.1200/OP.21.00858
   PubMedGoogle Scholar
• Pharmacogenetic associations for which the data support therapeutic management recommendations. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations. Accessed July 7, 2023.
   Google Scholar
• Human medicine European public assessment report (EPAR). Available from: https://www.ema.europa.eu/en/medicines. Accessed July 7, 2023.
   Google Scholar
• Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing; 2017. Available from: https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/. Accessed July 7, 2023.
   Google Scholar
• Dutch pharmacogenomics guidelines. Available from: https://upgx.eu/guidelines/. Accessed July 7, 2023.
   Google Scholar
• EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine; 2020. Available from: https://www.ema.europa.eu/en/documents/press-release/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine_en.pdf. Accessed July 7, 2023.
   Google Scholar
• US Food and Drug Administration. Highlights of prescribing information: camptosar (irinotecan); 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf. Accessed July 7, 2023.
   Google Scholar
• European Medicines Agency. Summary of product characteristics onivyde (irinotecan hydrochloride trihydrate); 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/onivyde-pegylated-liposomal-epar-product-information_en.pdf. Accessed July 7, 2023.
   Google Scholar
• Recommendations for pharmacogenetic testing by AIOM-SIF working group. Available from: https://www.aiom.it/wp-content/uploads/2019/10/2019_Racc-analisi-farmacogenetiche_v26.3.2020.pdf. Accessed July 7, 2023.
   Google Scholar
• EMQN’s EQA schemes: pharmacogenetics (panel testing). Available from: https://www.emqn.org/eqa-scheme-catalogue/. Accessed July 7, 2023.
   Google Scholar
• rs1648179549 RefSNP report. Available from: https://www.ncbi.nlm.nih.gov/snp/. Accessed July 7, 2023.
   Google Scholar
• Cheli S, Pietrantonio F, Clementi E, Falvella FS. LightSNiP assay is a good strategy for pharmacogenetics test. Front Pharmacol. 2015;6:114. doi:10.3389/fphar.2015.00114
   PubMed Web of Science ®Google Scholar
• rs17376848 RefSNP report. Available from: https://www.ncbi.nlm.nih.gov/snp/. Accessed July 7, 2023.
   Google Scholar
• rs763061658 RefSNP report. Available from: https://www.ncbi.nlm.nih.gov/snp/. Accessed July 7, 2023.
   Google Scholar
• Tafazoli A, Guchelaar HJ, Miltyk W, Kretowski AJ, Swen JJ. Applying next-generation sequencing platforms for pharmacogenomic testing in clinical practice. Front Pharmacol. 2021;12:693453. doi:10.3389/fphar.2021.693453
   PubMed Web of Science ®Google Scholar
• van der Wouden CH, van Rhenen MH, Jama WOM, et al. Development of the PGx-passport: a panel of actionable germline genetic variants for pre-emptive pharmacogenetic testing. Clin Pharmacol Ther. 2019;106(4):866–873. doi:10.1002/cpt.1489
   PubMed Web of Science ®Google Scholar
• Palmirotta R, Lovero D, Delacour H, Le Roy A, Cremades S, Silvestris F. Rare dihydropyrimidine dehydrogenase variants and toxicity by floropyrimidines: a case report. Front Oncol. 2019;9:139. doi:10.3389/fonc.2019.00139
   PubMed Web of Science ®Google Scholar
• Gentile G, Botticelli A, Lionetto L, et al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J. 2016;16(4):320–325. doi:10.1038/tpj.2015.56
   PubMed Web of Science ®Google Scholar
• Ruzzo A, Graziano F, Galli F, et al. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, Phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer. 2017;117(9):1269–1277. doi:10.1038/bjc.2017.289
   PubMed Web of Science ®Google Scholar
• Gross E, Busse B, Riemenschneider M, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One. 2008;3(12):e4003. doi:10.1371/journal.pone.0004003
   PubMed Web of Science ®Google Scholar
• Sharma MR, Joshi SS, Karrison TG, et al. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019;125(10):1629–1636. doi:10.1002/cncr.31938
   PubMed Web of Science ®Google Scholar
• Páez D, Tobeña M, Fernández-Plana J, et al. Pharmacogenetic clinical randomised Phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br J Cancer. 2019;120(2):190–195. doi:10.1038/s41416-018-0348-7
   PubMed Web of Science ®Google Scholar
• Karas S, Innocenti F. All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide. JCO Oncol Pract. 2022;18(4):270–277. doi:10.1200/OP.21.00624
   PubMedGoogle Scholar
• Etienne-Grimaldi MC, Boyer JC, Thomas F, et al. Collective work by the Group of Clinical Onco-Pharmacology (GPCO-Unicancer); French National Network of Pharmacogenetics (RNPGx). UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015;29(3):219–237. doi:10.1111/fcp.12117
   PubMed Web of Science ®Google Scholar
• Sissung TM, Barbier RH, Price DK, et al. Comparison of eight technologies to determine genotype at the UGT1A1 (TA)n repeat polymorphism: potential clinical consequences of genotyping errors? Int J Mol Sci. 2020;21(3):896. doi:10.3390/ijms21030896
   PubMed Web of Science ®Google Scholar